Cogent Biosciences Announces That Results From Its Phase 3 PEAK Trial Have Been Selected For Oral Presentation At The 2026 American Society Of Clinical Oncology Annual Meeting, May 29-June 2

Benzinga Newsdesk www.benzinga.com Neutral 80.5%

Neg 0% Neu 80.5% Pos 0%

Comments

No comments yet. Be the first!